Gilead: Updated Data From Remdesivir Study In Pediatric COVID-19 Patients

 Gilead Sciences Inc 

GILD -1.1%

 (Get Free Alerts for GILD) announced new data from an interim analysis of its ongoing, Phase 2/3 study of Veklury (remdesivir) in pediatric patients hospitalized with COVID-19.

• The data will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022).
• The latest data demonstrate that Veklury was generally well-tolerated among pediatric patients hospitalized with COVID-19, with a high proportion of participants showing clinical improvement and recovery. 
• Overall, no new safety findings for Veklury were noted, and 85% of patients showed clinical improvement based on the clinical ordinal scale, and the recovery rate was 83% at the last assessment (N=53).
• In January, the FDA expanded the pediatric Emergency Use Authorization (EUA) of Veklury to include non-hospitalized pediatric patients.

https://www.benzinga.com/general/biotech/22/02/25595856/gilead-shares-updated-data-from-remdesivir-study-in-pediatric-covid-19-patients